Free Trial

Immunome Q4 2022 Earnings Report

Immunome logo
$12.02 -0.42 (-3.38%)
(As of 12/17/2024 ET)

Immunome EPS Results

Actual EPS
-$0.64
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Immunome Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Immunome Announcement Details

Quarter
Q4 2022
Time
N/A
Musk threatens Liberal’s fake “energy crisis” (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

Immunome Earnings Headlines

A conspiracy Trump won’t unseal
New documentary reveals the lost wealth-building secret hidden deep within ancient religious texts from almost every civilization… an investment one expert says is “so perfect that only God could have created it.” Watch it now to discover how this asset that you’ve likely never considered before can produce returns so safe, secure, and endless it is nothing short of miraculous.
Immunome Inc.
Immunome files to sell 1.8M shares of common stock for holders
See More Immunome Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Immunome? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Immunome and other key companies, straight to your email.

About Immunome

Immunome (NASDAQ:IMNM), a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

View Immunome Profile

More Earnings Resources from MarketBeat

Upcoming Earnings